TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Single-Center, Phase 1 Clinical Study to Evaluate the Safety and the Efficacy of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia
Brief Summary: PNEUMOSTEM® is human umbilical cord blood derived mesenchymal stem cells and it is intended to treat premature infants with bronchopulmonary dysplasia. This study is to assess the safety and the efficacy of this study drug.


Options:
A: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control
B: Arm Label: EPO HIE Group; Type: EXPERIMENTAL; Interventions: Drug: Human recombinant erythropoietin, Procedure: EEG and Brain MRI, Biological: Nitric oxide measurement in the blood | Arm Label: Control HIE; Type: NO_INTERVENTION; Interventions: Procedure: EEG and Brain MRI, Biological: Nitric oxide measurement in the blood | Arm Label: Healthy Controls; Type: OTHER; Interventions: Biological: Nitric oxide measurement in the blood | Intervention Type: DRUG; Name: Human recombinant erythropoietin; Assigned to Arm(s): EPO HIE Group | Intervention Type: PROCEDURE; Name: EEG and Brain MRI; Assigned to Arm(s): Control HIE, EPO HIE Group | Intervention Type: BIOLOGICAL; Name: Nitric oxide measurement in the blood; Assigned to Arm(s): Control HIE, EPO HIE Group, Healthy Controls
C: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs
D: Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Single-Center, Phase 1 Clinical Study to Evaluate the Safety and the Efficacy of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia
Brief Summary: PNEUMOSTEM® is human umbilical cord blood derived mesenchymal stem cells and it is intended to treat premature infants with bronchopulmonary dysplasia. This study is to assess the safety and the efficacy of this study drug.


Options:
A: Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®
B: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control
C: Arm Label: Pneumostem®; Type: N/A; Interventions: Biological: Pneumostem® | Intervention Type: BIOLOGICAL; Name: Pneumostem®; Assigned to Arm(s): Pneumostem®
D: Arm Label: Neural progenitor cell; Type: EXPERIMENTAL; Interventions: Biological: neural progenitor cell | Arm Label: Paracrine factors; Type: EXPERIMENTAL; Interventions: Biological: Paracrine factors | Arm Label: Progenitor cell and paracrine factors; Type: EXPERIMENTAL; Interventions: Biological: progenitor cell and paracrine factors | Arm Label: Routine therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: neural progenitor cell; Assigned to Arm(s): Neural progenitor cell | Intervention Type: BIOLOGICAL; Name: Paracrine factors; Assigned to Arm(s): Paracrine factors | Intervention Type: BIOLOGICAL; Name: progenitor cell and paracrine factors; Assigned to Arm(s): Progenitor cell and paracrine factors

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.
Brief Summary: The purpose is to investigate tocilizumab administration in patients with moderately to severely or sight-threatening GO (Graves' ophthalmopathy) without response to treatment with corticoid intravenous pulses. Currently, these patients only have surgery as therapeutic alternative.

The principal aim of this study is to evaluate efficacy and safety of tocilizumab treatment in order to provide a better alternative to surgery for this patients.


Options:
A: Arm Label: Rituximab Intravenous Infusion; Type: EXPERIMENTAL; Interventions: Drug: Anti-CD20 (rituximab) | Arm Label: Placebo Intravenous Infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Anti-CD20 (rituximab); Assigned to Arm(s): Rituximab Intravenous Infusion | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo Intravenous Infusion
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Rituximab
C: Arm Label: Tocilizumab; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab (RoActemra®) | Arm Label: Sterile 0.9% Sodium Chloride; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile 0.9% Sodium Chloride | Intervention Type: DRUG; Name: Tocilizumab (RoActemra®); Assigned to Arm(s): Tocilizumab | Intervention Type: DRUG; Name: Sterile 0.9% Sodium Chloride; Assigned to Arm(s): Sterile 0.9% Sodium Chloride
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline | Arm Label: Teprotumumab; Type: EXPERIMENTAL; Interventions: Drug: teprotumumab | Intervention Type: DRUG; Name: teprotumumab; Assigned to Arm(s): Teprotumumab | Intervention Type: DRUG; Name: normal saline; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Randomised Clinical Trial of Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Brief Summary: The specific aims of the study are to test the following hypotheses:

* That there is a difference in change in visual acuity resulting from treatment with intravitreal bevacizumab compared with dexamethasone implant in eyes with advanced macular oedema
* That there is a difference in degree of resolution of macular oedema resulting from treatment with intravitreal bevacizumab compared with dexamethasone implant in eyes with advanced macular oedema
* That both intravitreal bevacizumab and dexamethasone implants have a manageable and acceptable safety profile in eyes with diabetic macular oedema


Options:
A: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A
B: Arm Label: Sham + intravitreal ranibizumab 0.3 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal ranibizumab 0.3 mg, Procedure: Sham injection | Arm Label: Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg; Type: EXPERIMENTAL; Interventions: Drug: intravitreal ranibizumab 0.3 mg, Drug: dexamethasone intravitreal implant | Intervention Type: DRUG; Name: intravitreal ranibizumab 0.3 mg; Assigned to Arm(s): Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg, Sham + intravitreal ranibizumab 0.3 mg | Intervention Type: DRUG; Name: dexamethasone intravitreal implant; Assigned to Arm(s): Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg | Intervention Type: PROCEDURE; Name: Sham injection; Assigned to Arm(s): Sham + intravitreal ranibizumab 0.3 mg
C: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
D: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Randomised Clinical Trial of Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Brief Summary: The specific aims of the study are to test the following hypotheses:

* That there is a difference in change in visual acuity resulting from treatment with intravitreal bevacizumab compared with dexamethasone implant in eyes with advanced macular oedema
* That there is a difference in degree of resolution of macular oedema resulting from treatment with intravitreal bevacizumab compared with dexamethasone implant in eyes with advanced macular oedema
* That both intravitreal bevacizumab and dexamethasone implants have a manageable and acceptable safety profile in eyes with diabetic macular oedema


Options:
A: Arm Label: Sham injection plus laser; Type: EXPERIMENTAL; Interventions: Behavioral: Sham injection, Procedure: Focal/grid laser | Arm Label: 0.5mg Ranibizumab plus laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Focal/grid laser | Arm Label: 4-mg Triamcinolone Acetonide plus Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone Acetonide, Procedure: Focal/grid laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 0.5mg Ranibizumab plus laser | Intervention Type: DRUG; Name: Triamcinolone Acetonide; Assigned to Arm(s): 4-mg Triamcinolone Acetonide plus Laser | Intervention Type: BEHAVIORAL; Name: Sham injection; Assigned to Arm(s): Sham injection plus laser | Intervention Type: PROCEDURE; Name: Focal/grid laser; Assigned to Arm(s): 0.5mg Ranibizumab plus laser, 4-mg Triamcinolone Acetonide plus Laser, Sham injection plus laser
B: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laser therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: intravitreous triamcinolone | Intervention Type: DRUG; Name: intravitreous triamcinolone; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: laser therapy; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone Acetonide | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Procedure: Standard of care laser photocoagulation | Intervention Type: DRUG; Name: fluocinolone acetonide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluocinolone Acetonide; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Standard of care laser photocoagulation; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles
Brief Summary: The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: OCP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levonorgestrel and ethinylestradiol | Arm Label: Oral estradiol valerate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Estradiol valerate | Intervention Type: DRUG; Name: Levonorgestrel and ethinylestradiol; Assigned to Arm(s): OCP | Intervention Type: DRUG; Name: Estradiol valerate; Assigned to Arm(s): Oral estradiol valerate
C: Arm Label: NuvaRing; Type: EXPERIMENTAL; Interventions: Drug: NuvaRing | Arm Label: Combined oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: marvelon | Intervention Type: DRUG; Name: NuvaRing; Assigned to Arm(s): NuvaRing | Intervention Type: DRUG; Name: marvelon; Assigned to Arm(s): Combined oral contraceptive pill
D: Arm Label: natural cycle; Type: OTHER; Interventions: Other: embryo transfer | Arm Label: hormonal cycle; Type: ACTIVE_COMPARATOR; Interventions: Other: embryo transfer | Intervention Type: OTHER; Name: embryo transfer; Assigned to Arm(s): hormonal cycle, natural cycle

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility of Novel Ambulatory Treatment Techniques in Venous Insufficiency
Brief Summary: Randomized controlled trial, a method used to implement the random allocation sequence is numbered containers.

The aim of the study is to compare operative treatment, ultrasound guided laser ablation and ultrasound guided foam sclerotherapy in occluding/ablating of insufficiency in great saphenous trunks. On the grounds of the available data, the study hypothesis is that using laser or operative treatment more than 20 percent better outcome can be achieved compared to foam sclerotherapy.


Options:
A: Arm Label: high ligation and stripping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: high ligation and stripping (surgery) | Arm Label: duplex guided foam sclerotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: FOAM | Intervention Type: PROCEDURE; Name: high ligation and stripping (surgery); Assigned to Arm(s): high ligation and stripping | Intervention Type: PROCEDURE; Name: FOAM; Assigned to Arm(s): duplex guided foam sclerotherapy
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: crossectomy and short stripping | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ultrasound guided sclerotherapy with foam | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endovenous laser therapy | Intervention Type: PROCEDURE; Name: crossectomy and short stripping; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: ultrasound guided sclerotherapy with foam; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: endovenous laser therapy; Assigned to Arm(s): 3
C: Arm Label: Operative treatment; Type: OTHER; Interventions: Procedure: Operative treatment | Arm Label: Laser ablation; Type: OTHER; Interventions: Procedure: Laser ablation | Arm Label: Foam sclerotherapy; Type: OTHER; Interventions: Procedure: Foam sclerotherapy | Intervention Type: PROCEDURE; Name: Operative treatment; Assigned to Arm(s): Operative treatment | Intervention Type: PROCEDURE; Name: Laser ablation; Assigned to Arm(s): Laser ablation | Intervention Type: PROCEDURE; Name: Foam sclerotherapy; Assigned to Arm(s): Foam sclerotherapy
D: Arm Label: Conventional Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Surgery | Arm Label: Radiofrequency Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency Ablation | Intervention Type: PROCEDURE; Name: Conventional Surgery; Assigned to Arm(s): Conventional Surgery | Intervention Type: PROCEDURE; Name: Radiofrequency Ablation; Assigned to Arm(s): Radiofrequency Ablation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions
Brief Summary: The objective of this study is to evaluate the safety and efficacy of preparing a vessel with photoablation with Spectranetics CVX-300® Excimer laser and laser catheters prior to local Paclitaxel delivery compared to local Paclitaxel delivery without initial photoablation


Options:
A: Arm Label: Conventional PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous transluminal angioplasty (PTA) | Arm Label: Drug coated balloon; Type: EXPERIMENTAL; Interventions: Combination Product: DCB | Intervention Type: DEVICE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): Conventional PTA | Intervention Type: COMBINATION_PRODUCT; Name: DCB; Assigned to Arm(s): Drug coated balloon
B: Arm Label: Drug Coated Balloon (DCB) Arm; Type: EXPERIMENTAL; Interventions: Procedure: Paclitaxel coated balloon angioplasty. | Arm Label: Drug Eluting Stents (DES) Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infrapopliteal Primary Drug Eluting Stenting | Intervention Type: PROCEDURE; Name: Paclitaxel coated balloon angioplasty.; Assigned to Arm(s): Drug Coated Balloon (DCB) Arm | Intervention Type: PROCEDURE; Name: Infrapopliteal Primary Drug Eluting Stenting; Assigned to Arm(s): Drug Eluting Stents (DES) Arm
C: Arm Label: Laser atherectomy and drug-coated balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems | Arm Label: Drug eluting Ballon PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems | Intervention Type: DEVICE; Name: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems; Assigned to Arm(s): Drug eluting Ballon PTA, Laser atherectomy and drug-coated balloon
D: Arm Label: Drug Eluting Balloon; Type: EXPERIMENTAL; Interventions: Device: IN.PACT Amphirion | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA | Intervention Type: DEVICE; Name: IN.PACT Amphirion; Assigned to Arm(s): Drug Eluting Balloon | Intervention Type: DEVICE; Name: Standard PTA; Assigned to Arm(s): Standard PTA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Steps to Health: Targeting Obesity in the Health Care Workplace
Brief Summary: The proposal of this study is to compare the effectiveness of two worksite weight management programs at Duke: Steps to Health (STH) ('usual standard of care') and the more extensive Steps to Health Plus! (STH+). We have added an additional follow-up, by invitation only, for participants in the study who agreed to be contacted for future research.


Options:
A: Arm Label: 1-800-QUIT-NOW Telephone Hotline; Type: OTHER; Interventions: Other: 1-800-QUIT-NOW Telephone Hotline | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Web-Based Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Web-Based Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: 1-800-QUIT-NOW Telephone Hotline; Assigned to Arm(s): 1-800-QUIT-NOW Telephone Hotline
B: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group
C: Arm Label: Steps to Health; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Steps to Health | Arm Label: Steps to Health Plus!; Type: EXPERIMENTAL; Interventions: Behavioral: Steps to Health Plus! | Arm Label: Observational Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Steps to Health; Assigned to Arm(s): Steps to Health | Intervention Type: BEHAVIORAL; Name: Steps to Health Plus!; Assigned to Arm(s): Steps to Health Plus!
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention

Answer: C